A practical guide for providers on helping patients locate Acyclovir during shortages. Covers availability tools, alternatives, workflow tips, and cost solutions.
As a healthcare provider, few things are more frustrating than writing a prescription you know is correct — only to learn your patient can't fill it. With Acyclovir experiencing intermittent supply disruptions since 2020, this has become an increasingly common scenario.
Whether your patient takes Acyclovir daily for genital herpes suppression, needs it urgently for a shingles outbreak, or requires IV therapy for HSV encephalitis, their inability to access the drug has real clinical consequences. This guide provides a practical framework for helping your patients navigate Acyclovir availability challenges in 2026.
As of early 2026, the Acyclovir supply picture looks like this:
For the latest shortage data, see our provider briefing on the Acyclovir shortage.
Several factors converge to create access problems:
When prescribing oral Acyclovir, default to 400 mg or 800 mg tablets — these are the most consistently stocked. If a patient needs 200 mg doses, prescribing 400 mg tablets with instructions to cut in half (where clinically appropriate) can avoid the 200 mg capsule availability gap.
For suppressive therapy dosing (400 mg BID for genital herpes), the 400 mg tablet is ideal. For shingles (800 mg 5 times daily), the 800 mg tablet eliminates the need for multiple lower-strength tablets.
Medfinder is a free tool that helps patients find pharmacies with their medication in stock. Instead of telling patients to "call around," you can direct them to medfinder.com where they can search by medication and zip code to see real-time availability.
Consider adding Medfinder to your post-visit instructions or medication handouts for patients who may face access issues.
If a patient reports they can't find Acyclovir, be prepared to pivot:
Pre-document a switch protocol in your EMR so you can respond quickly when patients call about Acyclovir access issues. Many EHRs allow you to create prescription "favorites" for standard alternative regimens.
Access isn't just about availability — it's also about affordability. Even when Acyclovir is in stock, uninsured patients may balk at the $70-$105 cash price for a month's supply. Proactive steps:
For a comprehensive resource to share with patients, direct them to our guide on saving money on Acyclovir.
For patients on daily suppressive therapy, writing a 90-day prescription with mail-order pharmacy fulfillment can:
For quick clinical reference when switching patients:
All three antivirals are Pregnancy Category B and require renal dose adjustment. Detailed equivalency and alternative information is available in our alternatives to Acyclovir guide.
Medication access is increasingly becoming a clinical responsibility, not just a logistical one. The Acyclovir shortage illustrates how supply chain fragility can directly impact patient outcomes — from delayed treatment of shingles (risking postherpetic neuralgia) to interrupted suppressive therapy (risking outbreak recurrence).
By prescribing strategically, keeping alternatives at the ready, and connecting patients with tools like Medfinder, you can minimize the impact of supply disruptions on your patients' care.
For the latest clinical and supply information, see our Acyclovir shortage briefing for providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
